Our data suggest that in MYB‐fusion‐positive BPDCN cases, venetoclax may represent a possible targeted therapy since the fusion drives BCL2 expression, at least in our model. This evidence concerns the gene MYB and CD4+/CD56+ hematodermic neoplasm.